Compare GKOS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | TNGX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.1B |
| IPO Year | 2015 | 2020 |
| Metric | GKOS | TNGX |
|---|---|---|
| Price | $146.06 | $28.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $126.92 | $21.78 |
| AVG Volume (30 Days) | 928.7K | ★ 6.4M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | $62,384,000.00 |
| Revenue This Year | $23.32 | N/A |
| Revenue Next Year | $27.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 32.33 | ★ 48.29 |
| 52 Week Low | $73.16 | $5.34 |
| 52 Week High | $148.62 | $34.39 |
| Indicator | GKOS | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 53.88 |
| Support Level | $96.44 | $27.65 |
| Resistance Level | N/A | $34.39 |
| Average True Range (ATR) | 5.65 | 2.05 |
| MACD | 1.60 | -0.25 |
| Stochastic Oscillator | 98.92 | 26.85 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.